SIM-0710 is under clinical development by Simcere Pharmaceutical Group and currently in the Phase I, Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect SIM-0710’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their SIM-0710 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

SIM-0710 overview

SIM-0710 is under development for the treatment of advanced colorectal cancer, non-small cell lung cancer and metastatic or unresectable advanced esophageal squamous cell carcinoma. The drug candidate is an Endu-PEG injection formulation which administered through the intravenous and parenteral route. Endu contains recombinant human endostatin as an active ingredient. It inhibits proinflammatory cytokines and vascular cell adhesion molecule (VCAM-1).

Simcere Pharmaceutical Group overview

Simcere Pharmaceutical Group (Simcere) is a pharmaceutical company discovers, develops, and markets branded generic and prescription pharmaceutical products. The company offers products in therapeutic areas such as anti-tumor, anti-infection, central nervous, cardiovascular, skeletal muscle, and others. Its product portfolio includes recombinant human endostatin injection, palonosetron hydrochloride injection, nedaplatin for injection, fluorouracil implants and lyvamlodipine besylate tablets, among others. Simcere’s products are used for the treatment of oncology, infectious diseases, neurology, anti-inflammation and also cardiovascular diseases. The company conducts research and development focused on low end generics and APIs to innovative medicines. The company’s precision medicine sector, Simcere diagnostics had strategic partnership t with Agena bioscience focused on Agena’s Massarray System for companion diagnostics and pharmacogenetic testing in China. Simcere is headquartered in Nanjing, Jiangsu, China

Quick View SIM-0710 LOA Data

Report Segments
  • Innovator
Drug Name
  • SIM-0710
Administration Pathway
  • Intravenous
  • Parenteral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.